@article{0e31c2b225c84dfea5fa583e82cd7f34,
title = "Quality Indicators in Patient Referral Documents for Heart Failure in Japan",
abstract = "This study examined quality indicators (QIs) for heart failure (HF) in patients{\textquoteright} referral documents (PRDs). We conducted a nationwide questionnaire survey to identify information that general practitioners (GPs) would like hospital cardiologists (HCs) to include in PRDs and that HCs actually include in PRDs. The percentage of GPs that desired each item included in PRDs was converted into a deviation score, and items with a deviation score of 50 were defined as QIs. We rated the quality of PRDs provided by HCs based on QI assessment. We received 281 responses from HCs and 145 responses from GPs. The following were identified as QIs: 1) HF cause; 2) B-type natriuretic peptide (BNP) or N-terminal pro-BNP concentration; 3) left ventricular ejection fraction or echocardiography; 4) body weight; 5) education of patients and their families on HF; 6) physical function, and 7) functions of daily living. Based on QI assessment, only 21.7% of HCs included all seven items in their PRDs. HCs specializing in HF and institutions with many full-time HCs were independently associated with including the seven items in PRDs. The quality of PRDs for HF varies among physicians and hospitals, and standardization is needed based on QI assessment.",
keywords = "Information sharing, Regional collaboration",
author = "Yoshiharu Kinugasa and Masakazu Saitoh and Toshimi Ikegame and Aoi Ikarashi and Kazushige Kadota and Kentaro Kamiya and Shun Kohsaka and Atsushi Mizuno and Isao Miyajima and Eisaku Nakane and Azusa Nei and Tatsuhiro Shibata and Hiroyuki Yokoyama and Sei Yumikura and Dai Yumino and Noboru Watanabe and Mitsuaki Isobe",
note = "Funding Information: E. Nakane received lecture fees from Boehringer Ingelheim Co. Ltd. and research grants from Daiichi-Sankyo Co. Ltd.; Nippon Shinyaku Co. Ltd.; Amgen Inc. Co. Ltd.; Nihon Medi-Physics Co. Ltd.; and Bayer Co. Ltd. T. Shibata received lecture fees from Otsuka Pharmaceutical Co. Ltd. and Daiichi-Sankyo Co. Ltd. M. Isobe received lecture fees from Otsuka Pharmaceutical Co. Funding Information: K. Kamiya received research grants from Eiken Chemical Co. Ltd. S. Kohsaka received lecture fees from Bristol-Myers Squibb Co. Ltd. and research grants from Daiichi-Sankyo Co. Ltd. Funding Information: From the 1Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan, 2Faculty of Health Science, Juntendo University, Tokyo, Japan, 3Sakakibara Heart Institute, Tokyo, Japan, 4Department of Cardiovascular Medicine, St Luke{\textquoteright}s International Hospital, Tokyo, Japan, 5Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan, 6Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan, 7Department of Cardiology, Keio University School of Medicine, Tokyo, Japan, 8Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, USA, 9Department of Clinical Nutrition, Chikamori Hospital, Kochi, Japan, 10Cardiovascular Center, the Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan, 11Toho University Medical Center Ohashi Hospital, Tokyo, Japan, 12Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan, 13Yokoyama Cardiology Clinic, Saitama, Japan, 14Yumikura Clinic, Tokyo, Japan, 15Yumino Medical, Tokyo, Japan, 16Department of Cardiology, Hokushin General Hospital, Nagano, Japan and 17Tokyo Medical and Dental University, Tokyo, Japan. This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI; No. 20K08403) and the Ministry of Health, Labour, and Welfare, Japan (No. 18062589). Address for correspondence: Yoshiharu Kinugasa, MD, Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, 36-1 Nishicho, Yonago, Tottori 683-8504, Japan. E-mail: ykinugasa-circ@tottori-u.ac.jp or Mitsuaki Isobe, MD, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu, Tokyo 183-0003, Japan. E-mail: misobe@shi.heart.or.jp Received for publication September 19, 2021. Revised and accepted December 2, 2021. Released in advance online on J-STAGE March 15, 2022. doi: 10.1536/ihj.21-617 All rights reserved by the International Heart Journal Association. Funding Information: Conflicts of interest: Y. Kinugasa received research grants from St. Jude Medical Japan Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.; Daiichi-Sankyo Co. Ltd.; Boston Scientific Co. Ltd.; Johnson & Johnson; Biotronik Japan Inc.; Japan Lifeline Co. Ltd.; Astellas; Teijin Pharma Ltd.; Mitsubishi Tanabe Pharma Co. Ltd.; Fukuda Denshi; Takeda Pharmaceutical Co. Ltd.; Ono Pharmaceutical Co. Ltd.; Public Health Research Foundation; Nihon Kohden Co. Ltd.; and Novartis Co. Ltd. K. Kadota received lecture fees from Daiichi-Sankyo Co. Ltd. Publisher Copyright: {\textcopyright} 2022, International Heart Journal Association. All rights reserved.",
year = "2022",
month = mar,
day = "30",
doi = "10.1536/ihj.21-617",
language = "English",
volume = "63",
pages = "278--285",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "2",
}